Low Dose Dexmedetomidine and Delirium After Cardiac Surgery

• Status: Completed
• Trial end date: 2019-08-12
• Target enrollment: 0
• Participant gender: All

Summary

Delirium after cardiac surgery can occur in up to 50% of the patients and has been shown to be significantly associated with increased morbidity and mortality. Advanced age is a significant risk factor of delirium.

Numerous studies have shown that sedation with high doses of Dexmedetomidine in the ICU reduces the incidence of postoperative delirium. On the other hand animal studies have shown neuroprotective effects of Dexmedetomidine by means of stimulating alpha2A-adrenoceptors.

It is not clear whether the administration of a low dose Dexmedetomidine in cardiac surgery would have any neuroprotective effects by stimulating the alpha 2A-receptors and as such would decrease the incidence of postoperative delirium.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Cliniques universitaires Saint-Luc- Université Catholique de Louvain
• Treatments: Dexmedetomidine

Criteria

Inclusion Criteria:

• Patients undergoing cardiac surgery with cardiopulmonary bypass

Exclusion Criteria:

• Hepatic dysfunction (hepatic function tests 3 times the normal value)

• Preoperative renal replacement therapy

• Preoperative delirium

• Emergency surgery not allowing neurologic evaluation by MMSE

• Mini invasive cardiac surgery

• Patients not speaking French